Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

NCT05578846 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Participants

Interventions

DRUG: Treatment A
DRUG: Treatment B
DRUG: Treatment C

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]